Insider Selling: Intuitive Surgical (NASDAQ:ISRG) Director Sells $28,303.20 in Stock

Key Points

• Director Amy Ladd sold 72 Intuitive Surgical shares for $28,303.20 at an average price of $393.10, reducing her direct holdings by 28.69% to 179 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Intuitive Surgical shares rose 2.0% to $401.23, while the company’s latest quarterly results exceeded expectations: earnings were $2.80 per share on $2.89 billion in revenue, with revenue up 18.4% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $509.02, although several firms recently lowered their targets. Institutional investors own approximately 83.64% of the stock.

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) Director Amy Ladd sold 72 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total transaction of $28,303.20. Following the sale, the director directly owned 179 shares of the company's stock, valued at $70,364.90. The trade was a 28.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Trading Up 2.0%

Shares of ISRG stock traded up $7.85 during mid-day trading on Tuesday, reaching $401.23. The stock had a trading volume of 4,122,251 shares, compared to its average volume of 2,469,939. The stock's 50-day moving average price is $392.47 and its two-hundred day moving average price is $443.35. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88. The firm has a market capitalization of $141.75 billion, a PE ratio of 45.96, a price-to-earnings-growth ratio of 2.74 and a beta of 1.47.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. Intuitive Surgical's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 earnings per share. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Institutional Trading of Intuitive Surgical

A number of hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC grew its holdings in shares of Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after buying an additional 731 shares during the last quarter. Sivia Capital Partners LLC lifted its position in Intuitive Surgical by 3.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider's stock valued at $504,000 after acquiring an additional 34 shares in the last quarter. Schnieders Capital Management LLC. boosted its stake in Intuitive Surgical by 38.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider's stock valued at $529,000 after purchasing an additional 268 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in shares of Intuitive Surgical during the second quarter valued at $200,000. Finally, Main Street Financial Solutions LLC boosted its position in shares of Intuitive Surgical by 92.4% during the second quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider's stock valued at $1,592,000 after buying an additional 1,407 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on ISRG. Jefferies Financial Group cut their price target on shares of Intuitive Surgical from $560.00 to $515.00 and set a "hold" rating on the stock in a report on Wednesday, April 22nd. Piper Sandler set a $357.44 price target on shares of Intuitive Surgical in a research report on Monday, July 27th. Sanford C. Bernstein lowered their price objective on shares of Intuitive Surgical from $750.00 to $685.00 and set an "outperform" rating for the company in a report on Friday, July 17th. Evercore set a $430.00 target price on Intuitive Surgical in a report on Monday, July 6th. Finally, TD Cowen lowered Intuitive Surgical from a "buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Twenty analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of "Moderate Buy" and a consensus price target of $509.02.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical’s second-quarter results exceeded expectations: revenue rose 18.4% year over year to $2.89 billion, while EPS reached $2.80 versus the $2.48 consensus estimate. Higher margins, continued adoption of its da Vinci and Ion platforms, and long-term demand for robotic-assisted surgery support the bullish case. Intuitive Surgical Just Beat Earnings
• Positive Sentiment: A bullish investor cited Intuitive Surgical’s potential once-per-decade hardware replacement cycle and approximately $8.6 billion cash position, arguing that the more than 30% year-to-date decline could create an attractive long-term entry point. The Number One Reason I Keep Buying Intuitive Surgical
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a “Moderate Buy” consensus and an average price target of $509.02. However, several firms recently lowered their targets, reflecting greater caution after the earnings report.
• Neutral Sentiment: Reported short interest was zero shares, implying no measurable short-selling pressure. The figure appears unusual and may reflect incomplete or unreliable data rather than a meaningful market signal.
• Negative Sentiment: Despite the earnings beat, investors remain concerned about slowing domestic procedure growth and whether the company’s roughly 46 P/E adequately reflects its growth prospects. Those concerns have contributed to the stock’s recent weakness. Intuitive Surgical Earnings and Valuation Analysis
• Negative Sentiment: Director Amy L. Ladd sold 472 shares across August 10–11, reducing her holdings by a substantial percentage, while EVP Gary Loeb sold 400 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their significance as a discretionary bearish signal but may still weigh modestly on sentiment.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon's hand movements into finer, scaled motions of small instruments inside the patient. Intuitive's business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source